Harm Reduction.
Ancillary medications and support strategies that biohackers and bodybuilders discuss for reducing harm — explained at mechanism level, so the community understands what these things do, what they don't do, and where the real risks sit.
What harm reduction means here
Performance enhancement has a cost ledger, and most of that ledger is boring: blood pressure creeping up, lipids drifting the wrong way, sleep getting thinner, blood counts thickening, mood narrowing. None of it announces itself loudly at first. Harm reduction is the discipline of watching that ledger before it becomes a crisis — and of refusing the two most common mistakes: ignoring a problem until it forces attention, and treating a side effect by stacking another drug on top without addressing the cause.
The core principle: monitoring before medicating
The order matters. Measure first, understand what moved and why, change the foundation where the foundation is the problem, and only then — with a clinician involved — consider whether a medication has a role at all. An ancillary drug that masks a marker without fixing the driver is not harm reduction; it is a cleaner-looking lab slip over the same risk. The pages in this section follow that order deliberately: foundations first, monitoring second, medication classes last, and only at mechanism level.
How to read these pages
Evidence is labeled, never conflated. Strong means replicated human evidence. Weaker means limited or mixed human data. Mechanism means the pharmacology makes sense but human outcomes are not established. Anecdote means community report, not evidence. Where a page says "discussed," it means discussed — not endorsed.
The topics
Heart & blood
Blood pressure, lipids, hematocrit, and cardiac strain — what to monitor, and why heavy training plus androgens raise these risks.
Liver & kidney
What liver and kidney markers mean in general terms, and the everyday loads — alcohol, painkillers, dehydration — that add up.
Hormones
Estrogen and prolactin concepts: aromatization, SERMs vs aromatase inhibitors at mechanism level, and why scheduled suppression can overshoot.
Sleep & breathing
Sleep apnea risk in heavier lifters and androgen users, the screening signals, and why a sleep study is the diagnostic step.
Mind & mood
Mood, irritability, and sleep disruption discussed in androgen use — and why getting support early beats pushing through.
Labs & monitoring
Which marker groups matter and what each group is for — without personalized schedules or lab-order links.
Ancillaries
The catalog: ancillary drugs and supplements grouped by category — mechanism level only.
Something wrong right now?
Some symptoms don't wait for a monitoring schedule. Chest pain, severe breathlessness, one-sided leg swelling, severe headache or vision changes, marked jaundice, and severe mood changes mean seek care now. The full list is on the red flags page — read it before you need it.
What this section is not
It is not a safety manual that makes risky use safe, and it is not permission. Some risks of androgen use are cumulative and only partly reversible, and no ancillary stack changes that. If the honest summary of a practice is "the monitoring burden and the risk are high and the benefit is cosmetic," these pages say that. Education that only ever reassures is marketing, not harm reduction.
Related: Learn for physiology and lab foundations, the Archive for individual compound records, Tools for the lab reference explorer. Educational content only. Not medical advice.